INR 123.5
(9.05%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 14.44 Million INR | 104.27% |
2022 | -338.44 Million INR | -54.81% |
2021 | -218.61 Million INR | -101.62% |
2020 | -108.43 Million INR | -14.02% |
2019 | -95.1 Million INR | 36.0% |
2018 | -148.58 Million INR | 3.33% |
2017 | -153.7 Million INR | -602.07% |
2016 | 30.61 Million INR | -71.7% |
2015 | 108.18 Million INR | 4.53% |
2014 | 103.5 Million INR | 36.7% |
2013 | 75.71 Million INR | -20.99% |
2012 | 95.82 Million INR | 4.5% |
2011 | 91.69 Million INR | 27.54% |
2010 | 71.89 Million INR | 30.97% |
2009 | 54.89 Million INR | 71.29% |
2008 | 32.04 Million INR | -18.29% |
2007 | 39.22 Million INR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | -1.2 Million INR | -2958.23% |
2023 Q1 | -4.16 Million INR | 24.95% |
2023 Q2 | 12.74 Million INR | 406.17% |
2023 Q3 | 6.61 Million INR | -48.12% |
2023 Q4 | -759 Thousand INR | -111.48% |
2023 FY | 14.44 Million INR | 104.27% |
2022 Q1 | -105.81 Million INR | -80.57% |
2022 Q2 | -115.05 Million INR | -8.73% |
2022 Q3 | -108.83 Million INR | 5.41% |
2022 Q4 | -5.54 Million INR | 94.9% |
2022 FY | -338.44 Million INR | -54.81% |
2021 FY | -218.61 Million INR | -101.62% |
2021 Q2 | -63.33 Million INR | -194.28% |
2021 Q4 | -58.59 Million INR | 29.09% |
2021 Q3 | -82.64 Million INR | -30.49% |
2021 Q1 | -21.52 Million INR | 65.14% |
2020 FY | -108.43 Million INR | -14.02% |
2020 Q1 | -21.1 Million INR | -44.76% |
2020 Q2 | 41.68 Million INR | 297.49% |
2020 Q3 | -17.79 Million INR | -142.68% |
2020 Q4 | -61.73 Million INR | -246.97% |
2019 Q4 | -14.58 Million INR | 41.9% |
2019 Q2 | -34.6 Million INR | -112.44% |
2019 Q3 | -25.09 Million INR | 27.46% |
2019 FY | -95.1 Million INR | 36.0% |
2019 Q1 | -16.28 Million INR | -11.14% |
2018 Q3 | -24.76 Million INR | 17.67% |
2018 FY | -148.58 Million INR | 3.33% |
2018 Q2 | -30.08 Million INR | 38.91% |
2018 Q1 | -49.24 Million INR | -52.25% |
2018 Q4 | -14.65 Million INR | 40.83% |
2017 Q3 | -33.33 Million INR | 30.67% |
2017 Q1 | -54.33 Million INR | -334.17% |
2017 FY | -153.7 Million INR | -602.07% |
2017 Q4 | -32.34 Million INR | 2.98% |
2017 Q2 | -48.08 Million INR | 11.5% |
2016 FY | 30.61 Million INR | -71.7% |
2016 Q4 | -12.51 Million INR | -287.95% |
2016 Q3 | 6.65 Million INR | -36.12% |
2016 Q1 | 24.4 Million INR | -34.07% |
2016 Q2 | 10.42 Million INR | -57.3% |
2015 FY | 108.18 Million INR | 4.53% |
2015 Q3 | 29.09 Million INR | 13.75% |
2015 Q2 | 25.57 Million INR | 55.02% |
2015 Q1 | 16.49 Million INR | -39.26% |
2015 Q4 | 37.02 Million INR | 27.26% |
2014 Q1 | 14.89 Million INR | -31.41% |
2014 Q4 | 27.16 Million INR | 20.43% |
2014 FY | 103.5 Million INR | 36.7% |
2014 Q2 | 38.89 Million INR | 161.16% |
2014 Q3 | 22.55 Million INR | -42.01% |
2013 Q2 | 19.57 Million INR | -0.56% |
2013 Q4 | 21.71 Million INR | 47.42% |
2013 FY | 75.71 Million INR | -20.99% |
2013 Q3 | 14.72 Million INR | -24.74% |
2013 Q1 | 19.68 Million INR | 6.24% |
2012 Q3 | 30.8 Million INR | 6.94% |
2012 Q2 | 28.8 Million INR | 62.71% |
2012 Q4 | 18.52 Million INR | -39.85% |
2012 Q1 | 17.7 Million INR | -14.49% |
2012 FY | 95.82 Million INR | 4.5% |
2011 Q2 | 26.2 Million INR | 0.0% |
2011 Q4 | 20.69 Million INR | -31.69% |
2011 FY | 91.69 Million INR | 27.54% |
2011 Q3 | 30.3 Million INR | 15.65% |
2010 FY | 71.89 Million INR | 30.97% |
2009 FY | 54.89 Million INR | 71.29% |
2008 FY | 32.04 Million INR | -18.29% |
2007 FY | 39.22 Million INR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Alembic Pharmaceuticals Limited | 5.75 Billion INR | 99.749% |
Aurobindo Pharma Limited | 42.2 Billion INR | 99.966% |
Glenmark Life Sciences Limited | 8.97 Billion INR | 99.839% |
Granules India Limited | 6.81 Billion INR | 99.788% |
Indoco Remedies Limited | 1.29 Billion INR | 98.883% |
Achyut Healthcare Limited | 4.43 Million INR | -225.372% |
Ajanta Pharma Limited | 19.67 Billion INR | 99.927% |
Alkem Laboratories Limited | 19.46 Billion INR | 99.926% |
Alpa Laboratories Limited | 184.49 Million INR | 92.173% |
AstraZeneca Pharma India Limited | 1.71 Billion INR | 99.159% |
Bajaj HealthCare Limited | - INR | -Infinity% |
Bliss GVS Pharma Limited | 1.23 Billion INR | 98.827% |
Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.979% |
Eris Lifesciences Limited | 5.18 Billion INR | 99.721% |
FDC Limited | 2.98 Billion INR | 99.516% |
Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 99.778% |
Gufic Biosciences Limited | 1.32 Billion INR | 98.914% |
Ind-Swift Laboratories Limited | 4.42 Billion INR | 99.673% |
Ipca Laboratories Limited | 7.98 Billion INR | 99.819% |
Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 97.158% |
Krebs Biochemicals & Industries Limited | -151.95 Million INR | 109.503% |
Lasa Supergenerics Limited | -458 Million INR | 103.153% |
Laurus Labs Limited | 3.94 Billion INR | 99.634% |
Lupin Limited | 28.04 Billion INR | 99.949% |
Mankind Pharma Limited | 21.51 Billion INR | 99.933% |
Medicamen Biotech Limited | - INR | -Infinity% |
Medico Remedies Limited | 100.3 Million INR | 85.603% |
Megasoft Limited | -121.1 Million INR | 111.924% |
NATCO Pharma Limited | 25.96 Billion INR | 99.944% |
Piramal Pharma Limited | 4.55 Billion INR | 99.683% |
RPG Life Sciences Limited | 2.29 Billion INR | 99.37% |
Sigachi Industries Limited | 1.47 Billion INR | 99.02% |
Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.986% |
Suven Pharmaceuticals Limited | 4.6 Billion INR | 99.687% |
Syncom Formulations (India) Limited | 249.25 Million INR | 94.207% |
Unichem Laboratories Limited | - INR | -Infinity% |
Wanbury Limited | 569.71 Million INR | 97.465% |
Windlas Biotech Limited | 1.29 Billion INR | 98.888% |
ZIM Laboratories Limited | 253.82 Million INR | 94.311% |
Zydus Lifesciences Limited | 43.1 Billion INR | 99.967% |
Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 100.351% |
Divi's Laboratories Limited | 33.08 Billion INR | 99.956% |
Hester Biosciences Limited | 364.81 Million INR | 96.042% |
Procter & Gamble Health Limited | 2.78 Billion INR | 99.482% |
Amrutanjan Health Care Limited | 457.54 Million INR | 96.844% |
Bal Pharma Limited | 233.9 Million INR | 93.827% |
Strides Pharma Science Limited | 5.22 Billion INR | 99.724% |
Venus Remedies Limited | 534.65 Million INR | 97.299% |
Aarti Pharmalabs Limited | 3.12 Billion INR | 99.538% |
Nectar Lifesciences Limited | 923.8 Million INR | 98.437% |
Shilpa Medicare Limited | 1.36 Billion INR | 98.943% |
Aarti Drugs Limited | 7.14 Billion INR | 99.798% |
IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 99.096% |
Suven Life Sciences Limited | -1.22 Billion INR | 101.178% |
Ind-Swift Limited | 1.22 Billion INR | 98.822% |
Valiant Laboratories Limited | - INR | -Infinity% |
J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 99.899% |
Solara Active Pharma Sciences Limited | -3.85 Billion INR | 100.375% |
Themis Medicare Limited | 392.58 Million INR | 96.322% |
Hikal Limited | 32.11 Million INR | 55.03% |
Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.943% |
Sequent Scientific Limited | - INR | -Infinity% |
Novartis India Limited | 626.5 Million INR | 97.695% |
Wockhardt Limited | -670 Million INR | 102.155% |
Jubilant Pharmova Limited | 5.18 Billion INR | 99.722% |
Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -59.229% |
Neuland Laboratories Limited | 5.31 Billion INR | 99.728% |
Morepen Laboratories Limited | 4.17 Billion INR | 99.654% |
Kilitch Drugs (India) Limited | 208.05 Million INR | 93.059% |
Mangalam Drugs & Organics Limited | 27.45 Million INR | 47.411% |